Correlative Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Correlative science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Correlative Science Today - Breaking & Trending Today

Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.
....

Nikhilc Munshi , Dana Farber Cancer Institute , Medicine At Harvard Medical School , Correlative Science , Jerome Lipper Multiple Myeloma Center , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Harvard Medical School , Multiple Myeloma , Onclive Tv ,

Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma

Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Nikhilc Munshi , Dana Farber Cancer Institute , Medicine At Harvard Medical School , Correlative Science , Jerome Lipper Multiple Myeloma Center , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Harvard Medical School ,

Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shared the long-term findings from the pivotal CARTITUDE-1 trial, and highlighted future directions for CAR T-cell therapy in this disease. ....

United States , Dana Farber Cancer Institute , Nikhilc Munshi , Jerome Lipper Multiple Myeloma Center , Harvard Medical School , Correlative Science , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Adaptive Biotechnologies , Karyopharm Therapeutics ,

Dr Munshi on the Future of CAR T-Cell Therapy in Multiple Myeloma

Nikhil C. Munshi, MD, discusses potential future directions for ciltacabtagene autoleucel and other CAR T-cell therapies in patients with multiple myeloma. ....

Nikhilc Munshi , Harvard Medical School , Jerome Lipper Multiple Myeloma Center , Dana Farber Cancer Institute , Correlative Science , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy ,

Dr Munshi on the Final Results of the CARTITUDE-1 Trial of Cilta-Cel in R/R Myeloma

Nikhil C. Munshi, MD, discusses the efficacy data from the final analysis of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. ....

Nikhilc Munshi , Dana Farber Cancer Institute , Medicine At Harvard Medical School , Correlative Science , Jerome Lipper Multiple Myeloma Center , Kraft Family Chair , Multiple Myeloma Immune Effector Cell Therapy , Harvard Medical School ,